In order to evaluate the prognostic value of TETs expression in AML, we further divided these patients into two groups based on median level of TET1/2/3 transcript respectively (TET1low vs. TET1high; TET2low vs. TET2high; TET3low vs. TET3high). This evidence concerns the gene TET1 and acute myeloid leukemia.